IL146455A0 - Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives - Google Patents
Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivativesInfo
- Publication number
- IL146455A0 IL146455A0 IL14645500A IL14645500A IL146455A0 IL 146455 A0 IL146455 A0 IL 146455A0 IL 14645500 A IL14645500 A IL 14645500A IL 14645500 A IL14645500 A IL 14645500A IL 146455 A0 IL146455 A0 IL 146455A0
- Authority
- IL
- Israel
- Prior art keywords
- protein aggregation
- imaging
- inhibiting
- isoindoline derivatives
- amyloid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13854399P | 1999-06-10 | 1999-06-10 | |
| PCT/US2000/015073 WO2000076969A1 (en) | 1999-06-10 | 2000-05-31 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL146455A0 true IL146455A0 (en) | 2002-07-25 |
Family
ID=22482508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14645500A IL146455A0 (en) | 1999-06-10 | 2000-05-31 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives |
Country Status (38)
| Country | Link |
|---|---|
| EP (1) | EP1192131B1 (pt) |
| JP (1) | JP2003502313A (pt) |
| KR (1) | KR20020012266A (pt) |
| CN (1) | CN1156445C (pt) |
| AP (1) | AP1398A (pt) |
| AT (1) | ATE272623T1 (pt) |
| AU (1) | AU777747B2 (pt) |
| BG (1) | BG106291A (pt) |
| BR (1) | BR0011446A (pt) |
| CA (1) | CA2373394A1 (pt) |
| CR (1) | CR6530A (pt) |
| CZ (1) | CZ20014366A3 (pt) |
| DE (1) | DE60012742T2 (pt) |
| DK (1) | DK1192131T3 (pt) |
| DZ (1) | DZ3262A1 (pt) |
| EA (1) | EA004405B1 (pt) |
| EE (1) | EE200100666A (pt) |
| ES (1) | ES2223531T3 (pt) |
| GE (1) | GEP20043407B (pt) |
| HK (1) | HK1046283B (pt) |
| HR (1) | HRP20020027A2 (pt) |
| HU (1) | HUP0201586A2 (pt) |
| IL (1) | IL146455A0 (pt) |
| IS (1) | IS6162A (pt) |
| MA (1) | MA26807A1 (pt) |
| MX (1) | MXPA01011112A (pt) |
| NO (1) | NO20015992L (pt) |
| NZ (1) | NZ515619A (pt) |
| OA (1) | OA11958A (pt) |
| PL (1) | PL352294A1 (pt) |
| PT (1) | PT1192131E (pt) |
| SI (1) | SI1192131T1 (pt) |
| SK (1) | SK17622001A3 (pt) |
| TR (1) | TR200200257T2 (pt) |
| UA (1) | UA64842C2 (pt) |
| WO (1) | WO2000076969A1 (pt) |
| YU (1) | YU86801A (pt) |
| ZA (1) | ZA200109164B (pt) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6972287B1 (en) | 1999-06-10 | 2005-12-06 | Pfizer Inc. | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits |
| BR0011728A (pt) * | 1999-06-10 | 2002-02-26 | Warner Lambert Co | Método de inibir a agregação de proteìna amilóide e imagem de depósitos de amilóide |
| PE20020394A1 (es) | 2000-08-18 | 2002-06-21 | Agouron Pharma | Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2 |
| CA2357450A1 (en) * | 2000-09-29 | 2002-03-29 | Warner-Lambert Company | Phenoxazine analogs useful as amyloid aggregation inhibitors and treatment of alzheimer's disease and disorders related to amyloidosis |
| GB0031302D0 (en) * | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Napthalene derivatives |
| AR042206A1 (es) * | 2002-11-26 | 2005-06-15 | Novartis Ag | Acidos fenilaceticos y derivados |
| GB2404855A (en) * | 2003-07-07 | 2005-02-16 | Pantherix Ltd | Arylcarboxylic acid derivatives and their therapeutic use |
| AR061623A1 (es) | 2006-06-26 | 2008-09-10 | Novartis Ag | Derivados de acido fenilacetico |
| US20100183513A1 (en) * | 2006-11-24 | 2010-07-22 | Wolfgang Froestl | N-(methyl) -1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's |
| WO2008099210A2 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| DK2684873T3 (en) * | 2008-06-09 | 2019-04-01 | Univ Muenchen Ludwig Maximilians | PHARMACEUTICALS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES CONNECTED WITH PROTEIN AGGREGATION AND / OR NEURODEGENERATIVE DISEASE |
| AU2010211109B2 (en) | 2009-02-06 | 2014-11-27 | Cellzome Limited | Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators |
| TWI461425B (zh) | 2009-02-19 | 2014-11-21 | Janssen Pharmaceuticals Inc | 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類 |
| MY152998A (en) | 2009-05-07 | 2014-12-31 | Janssen Pharmaceuticals Inc | Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators |
| MX2012000763A (es) | 2009-07-15 | 2012-02-08 | Janssen Pharmaceuticals Inc | Derivados sustituidos de triazol e imidazol como moduladores de la gamma secretasa. |
| PE20121511A1 (es) | 2010-01-15 | 2012-12-06 | Janssen Pharmaceuticals Inc | Novedosos derivados biciclicos de triazol sustituidos como moduladores de gamma secretasa |
| US8987276B2 (en) | 2011-03-24 | 2015-03-24 | Janssen Pharmaceuticals, Inc. | Substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators |
| KR101913135B1 (ko) | 2011-07-15 | 2018-10-30 | 얀센 파마슈티칼즈, 인코포레이티드 | 감마 세크레타제 조절 인자로서의 신규의 치환 인돌 유도체 |
| US9181245B2 (en) | 2012-05-16 | 2015-11-10 | Janssen Pharmaceuticals, Inc. | Substituted pyrido[1,2-a]pyrazines and substituted pyrido[1,2-a][1,4]diazepines for the treatment of (inter alia) Alzheimer's disease |
| WO2014096212A1 (en) | 2012-12-20 | 2014-06-26 | Janssen Pharmaceutica Nv | NOVEL TRICYCLIC 3,4-DIHYDRO-2H-PYRIDO[1,2-α]PYRAZINE-1,6-DIONE DERIVATIVES AS GAMMA SECRETASE MODULATORS |
| KR102171710B1 (ko) | 2013-01-17 | 2020-10-30 | 얀센 파마슈티카 엔.브이. | 감마 세크레타제 조절 인자로서의 신규 치환 피리도-피페라지논 유도체 |
| US10562897B2 (en) | 2014-01-16 | 2020-02-18 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators |
| JP6688445B2 (ja) * | 2014-04-14 | 2020-04-28 | シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | アミド誘導体およびそれらの薬学的に許容される塩、それらの製造方法およびそれらの医薬応用 |
| SI3186241T1 (sl) * | 2014-08-29 | 2021-03-31 | Chdi Foundation, Inc. | Sonde za slikanje Huntingtonovega proteina |
| HUE051972T2 (hu) | 2014-10-06 | 2021-04-28 | Vertex Pharma | Cisztás fibrózis transzmembrán konduktancia regulátor modulátorai |
| PL3436446T3 (pl) | 2016-03-31 | 2023-09-11 | Vertex Pharmaceuticals Incorporated | Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa |
| BR112019006213A2 (pt) | 2016-09-30 | 2019-06-18 | Vertex Pharma | modulador de regulador de condutância transmembranar de fibrose cística, composições farmacêuticas, métodos de tratamento e processo para fazer o modulador |
| PE20241131A1 (es) | 2016-12-09 | 2024-05-24 | Vertex Pharma | Modulador del regulador de conductancia de transmembrana de fibrosis quistica, composiciones farmaceuticas, metodos de tratamiento y proceso para producir el modulador |
| WO2018140186A1 (en) * | 2017-01-28 | 2018-08-02 | Kingchem Life Science Llc | A process for preparing 5-phenoxy-1(3h)isobenzofuranone |
| AU2018279646B2 (en) | 2017-06-08 | 2023-04-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| US11517564B2 (en) | 2017-07-17 | 2022-12-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| WO2019028228A1 (en) | 2017-08-02 | 2019-02-07 | Vertex Pharmaceuticals Incorporated | PROCESSES FOR THE PREPARATION OF PYRROLIDINE COMPOUNDS |
| CN109232533A (zh) * | 2017-09-28 | 2019-01-18 | 北京越之康泰生物医药科技有限公司 | 氮杂环类衍生物、其制备方法及其医药用途 |
| AU2018351533B2 (en) | 2017-10-19 | 2023-02-02 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
| CN111757874B (zh) | 2017-12-08 | 2024-03-08 | 弗特克斯药品有限公司 | 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法 |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| US11414439B2 (en) | 2018-04-13 | 2022-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| WO2023283425A1 (en) | 2021-07-09 | 2023-01-12 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552426A (en) * | 1994-04-29 | 1996-09-03 | Eli Lilly And Company | Methods for treating a physiological disorder associated with β-amyloid peptide |
-
2000
- 2000-05-31 EA EA200101133A patent/EA004405B1/ru not_active IP Right Cessation
- 2000-05-31 WO PCT/US2000/015073 patent/WO2000076969A1/en not_active Application Discontinuation
- 2000-05-31 AU AU53120/00A patent/AU777747B2/en not_active Ceased
- 2000-05-31 EE EEP200100666A patent/EE200100666A/xx unknown
- 2000-05-31 KR KR1020017015827A patent/KR20020012266A/ko not_active Application Discontinuation
- 2000-05-31 NZ NZ515619A patent/NZ515619A/en unknown
- 2000-05-31 CA CA002373394A patent/CA2373394A1/en not_active Abandoned
- 2000-05-31 JP JP2001503829A patent/JP2003502313A/ja active Pending
- 2000-05-31 IL IL14645500A patent/IL146455A0/xx unknown
- 2000-05-31 DE DE2000612742 patent/DE60012742T2/de not_active Expired - Fee Related
- 2000-05-31 YU YU86801A patent/YU86801A/sh unknown
- 2000-05-31 EP EP00938023A patent/EP1192131B1/en not_active Expired - Lifetime
- 2000-05-31 GE GE4625A patent/GEP20043407B/en unknown
- 2000-05-31 TR TR2002/00257T patent/TR200200257T2/xx unknown
- 2000-05-31 SI SI200030475T patent/SI1192131T1/xx unknown
- 2000-05-31 ES ES00938023T patent/ES2223531T3/es not_active Expired - Lifetime
- 2000-05-31 SK SK1762-2001A patent/SK17622001A3/sk unknown
- 2000-05-31 DK DK00938023T patent/DK1192131T3/da active
- 2000-05-31 DZ DZ003262A patent/DZ3262A1/fr active
- 2000-05-31 UA UA2001117664A patent/UA64842C2/uk unknown
- 2000-05-31 HU HU0201586A patent/HUP0201586A2/hu unknown
- 2000-05-31 MX MXPA01011112A patent/MXPA01011112A/es not_active Application Discontinuation
- 2000-05-31 OA OA1200100320A patent/OA11958A/en unknown
- 2000-05-31 PL PL00352294A patent/PL352294A1/xx not_active Application Discontinuation
- 2000-05-31 CN CNB008087288A patent/CN1156445C/zh not_active Expired - Fee Related
- 2000-05-31 AP APAP/P/2002/002389A patent/AP1398A/en active
- 2000-05-31 PT PT00938023T patent/PT1192131E/pt unknown
- 2000-05-31 BR BR0011446-4A patent/BR0011446A/pt not_active IP Right Cessation
- 2000-05-31 CZ CZ20014366A patent/CZ20014366A3/cs unknown
- 2000-05-31 AT AT00938023T patent/ATE272623T1/de not_active IP Right Cessation
-
2001
- 2001-11-06 ZA ZA200109164A patent/ZA200109164B/en unknown
- 2001-11-15 IS IS6162A patent/IS6162A/is unknown
- 2001-12-07 NO NO20015992A patent/NO20015992L/no not_active Application Discontinuation
- 2001-12-07 CR CR6530A patent/CR6530A/es not_active Application Discontinuation
-
2002
- 2002-01-03 MA MA26467A patent/MA26807A1/fr unknown
- 2002-01-09 BG BG106291A patent/BG106291A/bg unknown
- 2002-01-10 HR HR20020027A patent/HRP20020027A2/hr not_active Application Discontinuation
- 2002-10-30 HK HK02107877.1A patent/HK1046283B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0201586A2 (en) | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives | |
| HUP0202508A3 (en) | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | |
| EP1233753A4 (en) | COMPOSITION AND METHOD FOR THE TREATMENT OF MEDIUM EARTH IGNITION | |
| HK1040899A1 (en) | Method for improved imaging and photodynamic therapy | |
| NO985484L (no) | FremgangsmÕte og preparat for behandling og forhindring av hyperurikemi | |
| GB0029951D0 (en) | Method of combining reconstruction images | |
| IL146769A0 (en) | Method of sterilizing | |
| AU5085800A (en) | Method of magnetic resonance imaging | |
| IL136629A (en) | Methods and apparatus for permitting transactions across firewalls | |
| DE60008820D1 (de) | Bilderzeugungsverfahren und Bilderzeugungsgerät | |
| HUP0201966A3 (en) | Methods of treatment and drug screening methods | |
| AU5311800A (en) | Rhodanine derivatives for use in a method of inhibiting amyloid protein aggregation and imaging amyloid deposits | |
| EP1126480A4 (en) | MAGNETIC POWDER AND MANUFACTURING METHOD | |
| HUP0203364A3 (en) | Method for preparation of 3-substituted-4-arylquinolin-2-one derivatives | |
| AP2000001826A0 (en) | Echinocandin derivatives preparation method and application as anti-fungal agents | |
| EP1173189A4 (en) | ASIALOZYTOKINES AND TREATMENT OF LIVER DISEASES | |
| AU6979800A (en) | Device and method for the partial electrochemical treatment of bar-shaped elements | |
| GB2355213B (en) | Apparatus and method of recirculating electrodeionisation | |
| EP1138691A4 (en) | TECHNIQUE FOR INCREASING THE SOLUBILITY OF A PROTEIN | |
| IL150208A0 (en) | Compound and method for the treatment of pain | |
| IL146505A (en) | Methods for the preparation of tetrahydroisoquinolinephenol derivatives and some new such derivatives | |
| PL329663A1 (en) | Novel peptide derivatives of analgesic properties and method of obtaining them | |
| IL128903A0 (en) | Method and device for enhancement of blood related signal | |
| GB9912169D0 (en) | Method of preparation of an antipersirant salt | |
| PL333937A1 (en) | Method of and apparatus for obtaining minced meat |